Usefulness of Preoperative Transforming Growth Factor-Beta to Predict New Onset Atrial Fibrillation After Surgical Ventricular Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy

American Journal of Cardiology

Volumn 120, Issue 1, 2017, Pages 118-123

  Guo, Ying ^a   Wu, Xi ^a   Zheng, Xinxin ^a   Lu, Jie ^a   Wang, Shuiyun ^a   Huang, Xiaohong ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RHYTHM; HEART SURGERY; HOSPITAL DISCHARGE; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTERVENTRICULAR SEPTUM; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MUSCLE RESECTION; NEW-ONSET ATRIAL FIBRILLATION; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; VENTRICULAR SEPTAL MYECTOMY; ADVERSE EFFECTS; ATRIAL FIBRILLATION; BLOOD; CARDIOMYOPATHY, HYPERTROPHIC; CHINA; HEART SEPTUM; INCIDENCE; MIDDLE AGED; ODDS RATIO; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TIME FACTOR; TRENDS;

ADULT; ATRIAL FIBRILLATION; BIOMARKERS; CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; CHINA; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 85018239982     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.03.252     Document Type: Article

References (27)

1. El-Chami, M.F., Kilgo, P., Thourani, V., Lattouf, O.M., Delurgio, D.B., Guyton, R.A., Leon, A.R., Puskas, J.D., New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol 55 (2010), 1370–1376.
2. Bessissow, A., Khan, J., Devereaux, P.J., Alvarez-Garcia, J., Alonso-Coello, P., Postoperative atrial fibrillation in non-cardiac and cardiac surgery: an overview. J Thromb Haemost 13:Suppl 1 (2015), S304–S312.
3. Desai, M.Y., Bhonsale, A., Smedira, N.G., Naji, P., Thamilarasan, M., Lytle, B.W., Lever, H.M., Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation 128 (2013), 209–216.
4. Woo, A., Williams, W.G., Choi, R., Wigle, E.D., Rozenblyum, E., Fedwick, K., Siu, S., Ralph-Edwards, A., Rakowski, H., Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111 (2005), 2033–2041.
5. Ommen, S.R., Thomson, H.L., Nishimura, R.A., Tajik, A.J., Schaff, H.V., Danielson, G.K., Clinical predictors and consequences of atrial fibrillation after surgical myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 89 (2002), 242–244.
6. Purnomo, Y., Piccart, Y., Coenen, T., Prihadi, J.S., Lijnen, P.J., Oxidative stress and transforming growth factor-beta1-induced cardiac fibrosis. Cardiovasc Hematol Disord Drug Targets 13 (2013), 165–172.
7. Xiao, H., Lei, H., Qin, S., Ma, K., Wang, X., TGF-beta1 expression and atrial myocardium fibrosis increase in atrial fibrillation secondary to rheumatic heart disease. Clin Cardiol 33 (2010), 149–156.
8. Swartz, M.F., Fink, G.W., Sarwar, M.F., Hicks, G.L., Yu, Y., Hu, R., Lutz, C.J., Taffet, S.M., Jalife, J., Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol 60 (2012), 1799–1806.
9. Ayca, B., Sahin, I., Kucuk, S.H., Akin, F., Kafadar, D., Avsar, M., Avci, I.I., Gungor, B., Okuyan, E., Dinckal, M.H., Increased transforming growth factor-beta levels associated with cardiac adverse events in hypertrophic cardiomyopathy. Clin Cardiol 38 (2015), 371–377.
10. Wu, C.H., Hu, Y.F., Chou, C.Y., Lin, Y.J., Chang, S.L., Lo, L.W., Tuan, T.C., Li, C.H., Chao, T.F., Chung, F.P., Liao, J.N., Chen, S.A., Transforming growth factor-beta1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. Heart Rhythm 10 (2013), 10–15.
11. Kim, S.K., Pak, H.N., Park, J.H., Ko, K.J., Lee, J.S., Wi, J., Choi, J.I., Kim, Y.H., Serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Korean Circ J 40 (2010), 185–190.
12. On, Y.K., Jeon, E.S., Lee, S.Y., Shin, D.H., Choi, J.O., Sung, J., Kim, J.S., Sung, K., Park, P., Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J Thorac Cardiovasc Surg 137 (2009), 1515–1520.
13. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., Naidu, S.S., Nishimura, R.A., Ommen, S.R., Rakowski, H., Seidman, C.E., Towbin, J.A., Udelson, J.E., Yancy, C.W., 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 142 (2011), 1303–1338.
14. Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., Picard, M.H., Roman, M.J., Seward, J., Shanewise, J.S., Solomon, S.D., Spencer, K.T., Sutton, M.S., Stewart, W.J., Chamber Quantification Writing Group, American Society of Echocardiography's Guidelines and Standards Committee, European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005), 1440–1463.
15. Drinko, J.K., Nash, P.J., Lever, H.M., Asher, C.R., Safety of stress testing in patients with hypertrophic cardiomyopathy. Am J Cardiol 93 (2004), 1443–1444 A1412.
16. Amar, D., Zhang, H., Leung, D.H., Roistacher, N., Kadish, A.H., Older age is the strongest predictor of postoperative atrial fibrillation. Anesthesiology 96 (2002), 352–356.
17. Mathew, J.P., Fontes, M.L., Tudor, I.C., Ramsay, J., Duke, P., Mazer, C.D., Barash, P.G., Hsu, P.H., Mangano, D.T., Investigators of the Ischemia Research and Education Foundation, Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 291 (2004), 1720–1729.
18. Ayer, J.G., Almafragy, H.S., Patel, A.A., Hellyer, R.L., Celermajer, D.S., Body mass index is an independent determinant of left atrial size. Heart Lung Circ 17 (2008), 19–24.
19. Turagam, M.K., Mirza, M., Werner, P.H., Sra, J., Kress, D.C., Tajik, A.J., Jahangir, A., Circulating biomarkers predictive of postoperative atrial fibrillation. Cardiol Rev 24 (2016), 76–87.
20. Khan, R., Sheppard, R., Fibrosis in heart disease: understanding the role of transforming growth factor-β 1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 118 (2006), 10–24.
21. Lee, K.W., Everett, T.H., Rahmutula, D., Guerra, J.M., Wilson, E., Ding, C., Olgin, J.E., Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114 (2006), 1703–1712.
22. Nakatani, Y., Nishida, K., Sakabe, M., Kataoka, N., Sakamoto, T., Yamaguchi, Y., Iwamoto, J., Mizumaki, K., Fujiki, A., Inoue, H., Tranilast prevents atrial remodeling and development of atrial fibrillation in a canine model of atrial tachycardia and left ventricular dysfunction. J Am Coll Cardiol 61 (2013), 582–588.
23. Ahimastos, A.A., Aggarwal, A., Savarirayan, R., Dart, A.M., Kingwell, B.A., A role for plasma transforming growth factor-beta and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?. Atherosclerosis 209 (2010), 211–214.
24. Matt, P., Schoenhoff, F., Habashi, J., Holm, T., Van, E.C., Loch, D., Carlson, O.D., Griswold, B.F., Fu, Q., De, B.J., Circulating transforming growth factor-beta in Marfan syndrome. Circulation 120 (2009), 526–532.
25. Kataoka, N., Nishida, K., Kinoshita, K., Sakamoto, T., Nakatani, Y., Tsujino, Y., Mizumaki, K., Inoue, H., Kinugawa, K., Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53. Heart Vessels 31 (2016), 2053–2060.
26. Ogo, T., Chowdhury, H.M., Yang, J., Long, L., Li, X., Torres Cleuren, Y.N., Morrell, N.W., Schermuly, R.T., Trembath, R.C., Nasim, M.T., Inhibition of overactive transforming growth factor-beta signaling by prostacyclin analogs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 48 (2013), 733–741.
27. Yan, Y., Wang, X.J., Li, S.Q., Yang, S.H., Lv, Z.C., Wang, L.T., He, Y.Y., Jiang, X., Wang, Y., Jing, Z.C., Elevated levels of plasma transforming growth factor-beta1 in idiopathic and heritable pulmonary arterial hypertension. Int J Cardiol 222 (2016), 368–374.